GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

imetelstat   Click here for help

GtoPdb Ligand ID: 13625

Synonyms: GRN-163 | GRN163 | Rytelo®
Approved drug
imetelstat is an approved drug (FDA (2024))
Compound class: Nucleic acid
Comment: Imetelstat is a lipid (palmitoyl) conjugated thio-phosphoramidate oligonucleotide-based telomerase (TERT) inhibitor [1]. It binds competitively to the RNA template region of the enzyme and blocks its catalytic action and its interaction with telomeres [3]. It was developed for the treatment of myeloid hematologic malignancies.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OC[C@@H]1[C@H](C[C@H](N2C=C(C)C(=O)NC2=O)O1)NP(=S)(O)OC[C@@H]3[C@H](C[C@H](N4C=NC5=C4N=CN=C5N)O3)NP(=S)(O)OC[C@@H]6[C@H](C[C@H](N7C=NC8=C7N=C(N)NC8=O)O6)NP(=S)(O)OC[C@@H]9[C@H](C[C@H](N%10C=NC%11=C%10N=C(N)NC%11=O)O9)NP(=S)(O)OC[C@@H]%12[C@H](C[C@H](N%13C=NC%14=C%13N=C(N)NC%14=O)O%12)NP(=S)(O)OC[C@@H]%15[C@H](C[C@H](N%16C=C(C)C(=O)NC%16=O)O%15)NP(=S)(O)OC[C@@H]%17[C@H](C[C@H](N%18C=C(C)C(=O)NC%18=O)O%17)NP(=S)(O)OC[C@@H]%19[C@H](C[C@H](N%20C=NC%21=C%20N=CN=C%21N)O%19)NP(=S)(O)OC[C@@H]%22[C@H](C[C@H](N%23C=NC%24=C%23N=C(N)NC%24=O)O%22)NP(=S)(O)OC[C@@H]%25[C@H](C[C@H](N%26C=NC%27=C%26N=CN=C%27N)O%25)NP(=S)(O)OC[C@@H]%28[C@H](C[C@H](N%29C=CC(=NC%29=O)N)O%28)NP(=S)(O)OC[C@@H]%30[C@H](C[C@H](N%31C=NC%32=C%31N=CN=C%32N)O%30)NP(=S)(O)OC[C@@H]%33[C@H](C[C@H](N%34C=NC%35=C%34N=CN=C%35N)O%33)N)O
Isomeric SMILES CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OC[C@@H]9[C@H](C[C@@H](O9)N%10C=NC%11=C%10N=C(NC%11=O)N)NP(=S)(O)OC[C@@H]%12[C@H](C[C@@H](O%12)N%13C=NC%14=C%13N=C(NC%14=O)N)NP(=S)(O)OC[C@@H]%15[C@H](C[C@@H](O%15)N%16C=C(C(=O)NC%16=O)C)NP(=S)(O)OC[C@@H]%17[C@H](C[C@@H](O%17)N%18C=C(C(=O)NC%18=O)C)NP(=S)(O)OC[C@@H]%19[C@H](C[C@@H](O%19)N%20C=NC%21=C(N=CN=C%21%20)N)NP(=S)(O)OC[C@@H]%22[C@H](C[C@@H](O%22)N%23C=NC%24=C%23N=C(NC%24=O)N)NP(=S)(O)OC[C@@H]%25[C@H](C[C@@H](O%25)N%26C=NC%27=C(N=CN=C%27%26)N)NP(=S)(O)OC[C@@H]%28[C@H](C[C@@H](O%28)N%29C=CC(=NC%29=O)N)NP(=S)(O)OC[C@@H]%30[C@H](C[C@@H](O%30)N%31C=NC%32=C(N=CN=C%32%31)N)NP(=S)(O)OC[C@@H]%33[C@H](C[C@@H](O%33)N%34C=NC%35=C(N=CN=C%35%34)N)N)O
InChI InChI=1S/C148H211N68O53P13S13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-97(218)160-34-69(217)38-255-282(242,295)256-51-95-74(25-102(261-95)207-37-68(4)136(221)191-148(207)229)195-274(234,287)249-45-89-78(29-106(264-89)212-61-175-115-124(155)165-56-170-129(115)212)199-277(237,290)252-48-92-81(32-109(267-92)215-64-178-118-132(215)183-143(158)187-139(118)224)202-280(240,293)254-50-94-82(33-110(269-94)216-65-179-119-133(216)184-144(159)188-140(119)225)203-281(241,294)253-49-93-79(30-107(268-93)213-62-176-116-130(213)181-141(156)185-137(116)222)200-278(238,291)246-42-86-72(23-100(260-86)205-35-66(2)134(219)189-146(205)227)193-272(232,285)245-41-85-73(24-101(259-85)206-36-67(3)135(220)190-147(206)228)194-273(233,286)248-44-88-77(28-105(263-88)211-60-174-114-123(154)164-55-169-128(114)211)198-276(236,289)251-47-91-80(31-108(266-91)214-63-177-117-131(214)182-142(157)186-138(117)223)201-279(239,292)250-46-90-76(27-104(265-90)210-59-173-113-122(153)163-54-168-127(113)210)197-275(235,288)244-40-84-71(22-99(258-84)204-20-19-96(150)180-145(204)226)192-271(231,284)247-43-87-75(26-103(262-87)209-58-172-112-121(152)162-53-167-126(112)209)196-270(230,283)243-39-83-70(149)21-98(257-83)208-57-171-111-120(151)161-52-166-125(111)208/h19-20,35-37,52-65,69-95,98-110,217H,5-18,21-34,38-51,149H2,1-4H3,(H,160,218)(H,242,295)(H2,150,180,226)(H2,151,161,166)(H2,152,162,167)(H2,153,163,168)(H2,154,164,169)(H2,155,165,170)(H,189,219,227)(H,190,220,228)(H,191,221,229)(H2,192,231,284)(H2,193,232,285)(H2,194,233,286)(H2,195,234,287)(H2,196,230,283)(H2,197,235,288)(H2,198,236,289)(H2,199,237,290)(H2,200,238,291)(H2,201,239,292)(H2,202,240,293)(H2,203,241,294)(H3,156,181,185,222)(H3,157,182,186,223)(H3,158,183,187,224)(H3,159,184,188,225)/t69?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,270?,271?,272?,273?,274?,275?,276?,277?,278?,279?,280?,281?,282?/m0/s1
InChI Key LVZYXEALRXBLJZ-ISQYCPACSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Approved to treat low to intermediate risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia [2]. Clinical trials in advanced solid tumour types have been terminated/withdrawn.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02598661 Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Phase 2/Phase 3 Interventional Geron Corporation
NCT04576156 A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Phase 3 Interventional Geron Corporation
External links Click here for help
For extended ADME data see the following:

Drugs.com